Literature review · Muscle & strength

CJC-1295 (no DAC)

The cited long-acting CJC-1295 literature is related background, not direct evidence for a no-DAC listing.

By HeartPep · Reviewed · 2 selected source records

Buy from HeartPep.com

Laboratory research only. Not for human or veterinary use.

At a glance

The selected source concerns a different, albumin-binding GHRF analogue in cells and rats. No direct study of these exact supplier-labelled materials was verified for this entry.

Identity & scope

Both catalogue aliases explicitly say no DAC. The supplied label alone does not fully document sequence, modifications or formulation. We do not silently equate this material with the albumin-binding analogue.

Catalogue labels covered: CJC 1295 N/Dac; CJC-1295 No DAC.

What the research shows

  • The related paper explains why an albumin-binding modification changes persistence and why it matters when reading CJC literature.

Critical interpretation

The missing modification changes the identity question

The FDA chemistry review treats CJC-1295 and CJC-1295 DAC as distinct active moieties and lists salt forms separately. That is a concrete reason to resist treating no DAC as a minor wording difference. Its 2024 review did not identify human studies of the specified no-DAC free base or acetate. This is a dated evidence finding, not proof that no later research exists or a current regulatory conclusion. [2]

Why the related rat paper remains background

The Jetté experiment deliberately joined GHRF-derived molecules to albumin to extend persistence, then measured activity in pituitary cells and rats. Removing that design feature removes a central reason for citing the prolonged exposure. The paper can explain the development programme, but cannot provide the half-life or outcomes of a no-DAC material. For a literature search to become directly applicable, its molecular specification must first match the material under discussion. [1]

Limitations & uncertainties

  • The cited preclinical results cannot establish no-DAC pharmacokinetics, human outcomes or nasal absorption.
  • A similar compound name is insufficient evidence of molecular equivalence.

Open research questions

  • What exact sequence, terminal groups and chemical form does no DAC identify here?
  • Is there a primary experiment on that precise molecule and the intended research model?

Selected papers & source records

Download bibliography
Animal studyRelated preparationAbstract / record checked

1. Human growth hormone-releasing factor (hGRF)1-29-albumin bioconjugates activate the GRF receptor on the anterior pituitary in rats: identification of CJC-1295 as a long-lasting GRF analog (opens in a new tab)

Jetté L, Léger R, Thibaudeau K, et al. (2005). Endocrinology. DOI: 10.1210/en.2004-1286 (opens in a new tab) · PMID 15817669

Design & population
Chemical synthesis, cultured rat pituitary-cell assays and pharmacokinetic experiments in male rats.
What the study found
Albumin-binding hGRF analogues retained activity in cells. The selected CJC-1295 analogue stimulated rat GH secretion and remained detectable beyond 72 hours.
Limits on interpretation
This work concerns an albumin-binding analogue. It does not test a no-DAC catalogue product or show muscle or strength benefits in people.
Technical referenceIdentity / technical contextFull text consulted

2. FDA Evaluation of CJC-1295-Related Bulk Drug Substances, Pharmacy Compounding Advisory Committee briefing document (opens in a new tab)

U.S. Food and Drug Administration. (2024). FDA briefing document, December 4, 2024 meeting.

Design & population
Official evaluation of five named CJC-1295-related substances, including chemical identity and the scope of identified clinical evidence. Relevant chemistry and clinical-evidence sections were consulted.
What the study found
The document distinguishes the no-DAC and DAC active moieties and separate salt forms. FDA did not identify human studies of the specified no-DAC free base or acetate in its review.
Limits on interpretation
A dated government evidence and identity review, not an intervention trial or a current legal-status determination. It does not authenticate any supplier material.

Search & review scope

Targeted web searches of PubMed-indexed primary research and original journal records. Selected abstracts and citation metadata were checked; full-text sections were consulted for the records explicitly labelled full-text. Retrieved records and targeted notice searches were also checked for visible corrections or retractions.. Checked 9 November 2026.

Selected primary background research plus an explicitly labelled FDA identity/evidence review; no direct trial of the exact supplier-labelled no-DAC material was verified.

Narrative selection, not a systematic review, comprehensive safety assessment or complete retraction audit. PubMed/PMC full-text access was intermittent. An abstract or selected-section review cannot replace appraisal of the complete methods, supplements and underlying data. Absence from this selection does not establish absence of research.

Recorded search terms
  • site.pubmed.ncbi.nlm.nih.gov CJC-1295 no DAC modified GRF 1-29 trial
  • site.fda.gov CJC-1295 without DAC tetrasubstituted GHRH 2024 chemistry review

Read the collection’s methods and editorial limits. For formal research, assess and cite the original paper.

Cite this review

HeartPep. CJC-1295 (no DAC): literature review. HeartPep literature library. Reviewed 9 November 2026. https://heartpep.com/us/research/library/cjc-1295-no-dac.

HeartPep is the commercial publisher of this secondary summary. It is not a peer-reviewed primary paper. Cite the original studies for their findings.

Buy from HeartPep.com

Laboratory research only. Not for human or veterinary use.

← All reviews and reference notes